Lymphoma Immunotherapy
In Situ Vaccination • Cancer Vaccines • T-cell Priming • CAR-T Therapy
What do we do?
As part of the Lymphoma Immunotherapy Program at The Tisch Cancer Institute at The Icahn School of Medicine at Mount Sinai, the Brody Lab studies basic and applied tumor immunology for the development of cancer immunotherapies, particularly for lymphomas and melanomas. We aim to improve cancer vaccines by priming anti-tumor responses at the the tumor site of each patient (in situ vaccine). Our lab has the relatively unique opportunity to perform correlative studies on primary patient tumor samples from early phase clinical trials and to continually develop advancements in those trials based on what is learned.
Pre-ISV Treatment
9-months Post-Treatment
In Situ Vaccination
in situ vaccination, a vaccine that is created at the tumor site in cancer patients, with the goal of activating a specific anti-tumor immune response that can target the primary tumor site but also other cancer cells that have metastasized throughout the body.
Bystander T-cell killing
Heterogeneous tumors can evade immune clearance by various mechanisms, including antigen loss or editing. Can off-target T cell killing be enhanced?
T cell priming
Cross-presentation is vital to tumor-antigen CD8 responses. To what degree are immunotherapies generating activated T cell signatures?
Immunotransplantation
Adoptive T cell therapy is a rapidly evolving and growing treatment. How can the immune system be modulated to optimize its efficacy?
Seeking Post-Doctoral Fellow.
Position available immediately. Responsibilities include but are not limited to performing cellular and molecular immunology techniques such as Flow Cytometry, ELISA, Luminex, and studies with animals as well as primary patient specimens.
